A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors

NCT07695142 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

275

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor (Phase 1)

Interventions

DRUG: HSK46256

Sponsor

Haisco Pharmaceutical Group Co., Ltd.